Search PubMed⌕ Search

Biomedical subjects

J Crouzet

Publications and source records attributed to J Crouzet.

At least 109 records · Page 6Linked to original sources
PubMed1982

[Treatment of severe or vasculitis associated forms of rheumatoid arthritis by plasma exchanges (author's transl)].

Five patients with typical seropositive rheumatoid arthritis were treated by plasma exchange. All patients had severe affections resistant to conventional treatment, while in four cases the disease involved extra-articular localizations: rheumatoid nodules (3 cases), polyneuritis (1 case), skin necrosis (1 case). Each patient received between 5 and 10 plasma exchanges over a period of 3 to 4 weeks. No major complications were observed. Immediate results were very good in all cases, as shown by absence of clinical expression of the arthritis, marked regression in extra-articular symptoms, and reduction in erythrocyte sedimentation rate without parallel alterations in rheumatoid factor levels. Improvement lasted for only a few weeks in 3 patients, in one case preceded by an acutely painful episode. In the remaining 2 cases, with associated vasculitis, improvement has been sustained for a period that now exceeds one year. Results are compared with those reported in the published literature, and the mode of action and indications for plasma exchange in rheumatoid arthritis discussed.

Adult↗
PubMed1980

Fabry's disease.

Explore the source record for details and available documents.

Biopsy↗
PubMed1980

[Hypophosphoremic osteomalacia secondary to benign connective tissue tumors: a report on three unusual cases with vitamin D metabolites measurements (author's transl)].

Three cases of benign connective tissue tumors (intracranial frontal hemangiopericytoma, rectosigmoid hemangioma, intraspinal neurinoma) associated with hypophosphoremic osteomalacia and reduction in plasma 1-25 (OH)2D levels are described. Rapid reversal of biological anomalies and subsequent recovery from clinical manifestations were observed after tumor ablation. Twenty-two identical cases have been reported in the published literature. The sharp- fall in 1-25 (OH)2D levels without secondary hypocalcemia or hyperparathyroidism suggests that intestinal absorption of calcium is not entirely dependent on this metabolite. Increased phosphoremia without a parallel rise in 1-25 (OH)2D levels was noted in one case. The possibility of an existing connective tissue tumor should be explored in all cases of hypophosphoremic osteomalacia.

Adult↗
PubMed1979

[Physiopathology of osteoporosis (author's transl)].

Osteoporosis is the result of the progressive loss of bone substance which occurs during a lifetime. Its histomorphological characteristics have been well-defined and it appears to be a single entity more particularly related to the general problem of cellular senescence. The rate at which bone is lost can be influenced by many events or general factors, known or unknown, which are capable of accelerating or slowing down its progression. The period when the fracture threshold is passed appears to depend on a bone mass which is weak at the end of the growth period, followed by genetic, mechanical--related more specifically to insufficient muscular activity--, hormonal-hypo-oestrogenemia-factors, and pathological episodes of more rapid demineralization (immobilization, corticotherapy) which become more irreversible with advancing age.

Adrenal Cortex Hormones↗
PubMed1978

[Pyrithioxine a new basic treatment of rheumatoid polyarthritis: initial study of 72 cases with a 6-month follow-up].

Pyrithioxine has certain chemical resemblances to penicillamine and is used as original treatment in a series of 72 cases of rheumatoid arthritis over a period of six months in a dose of 600 mgs daily. Results were favourable in 63% of cases with important lowering of the articular index, return to normal of the sedimentation rate and less frequently a reversal of the Waaler-Rose reaction. Secondary complications were essentially muco-cutaneous, sometimes gastric and necessitated stopping treatment in 15% of cases. No other serious side effect has been observed. When compared with penicillamine pyrithioxine would appear less efficacious but better tolerated. The usefulness of this new medicament in the treatment of rheumatoid arthritis needs to be further explored.

Adult↗
PubMed1977

[The action of D-penicillamine on the distribution of T and B-lymphocytes in rheumatoid arthritis].

Comparative study of the numbers of T and B lymphocytes in cases of rheumatoid polyarthritis treated and untreated with D-penicillamine shows that in the untreated subjects the distribution of these two types of lymphocytes is comparable with that in normal subjects and that D-penicillamine does not alter this distribution. This purely quantitative investigation does not rule out the possibility of functional modifications in the cells studied.

Adult↗
PubMed1977

[Pyrithioxine: a new basic treatment of rheumatoid arthritis. Open study of 60 cases with a follow-up of 6 months].

Pyrithioxine, a chemical compound with several points in common with penicillinamine, was used for six months as the basic treatment in a series of 60 cases of rheumatoid arthritis, in a dose of 600 mg per day. The results were favourable in 60 per cent of cases, with a marked fall in articular index, a return to normal of sedimentation rate and, less commonly, negativisation of the Rose-Waaler reaction. Side effects were essentially cutaneo-mucosal (pruitus, rash) and necessitated the interruption of treatment in 16.5 per cent of cases. No complications were seen. Compared with penicillinamine, pyrithioxine appears to be less effective but better tolerated. The place of this new basic drug in the basic treatment of rheumatoid arthritis remains to be precisely determined.

Adult↗
PubMed1977

[Study of optimal posology of penicillamine in the treatment of common rheumatoid polyarthritis (apropos of a personal series of 200 cases)].

A comparison of two series of patients with rhe,matic polyarthritis, the one (n = 140) treated with dosage equal to or higher than 900 mg, the other (n = 60) with dosage between 600 and 750 mg, did not reveal significant difference in clinical and biological efficacy. The number of side-effects was not significantly reduced by lower dosage, except for digestive tract disorders. A reduction of dosage does, therefore, not permit less strict supervision and monitoring for side-effects of treatment.

Arthritis, Rheumatoid↗
PubMed1977

[Action of some factors on P.R. toxin excretion].

Conditions of P.R. toxin production by 4 strains of Penicillium roqueforti are tested. This production occurs only in specific conditions of culture. Some strains do not produce P.R. toxin.

Epoxy Compounds↗